| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6727253 | CLINIGEN | Treatment of accidental extravasation of anthracyclines |
Mar, 2020
(4 years ago) | |
Totect is owned by Clinigen.
Totect contains Dexrazoxane Hydrochloride.
Totect has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Totect are:
- US6727253
Totect was authorised for market use on 06 September, 2007.
Totect is available in injectable;injection dosage forms.
Totect can be used as treatment of extravasation resulting from iv anthracycline chemotherapy.
The generics of Totect are possible to be released after 13 March, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Sep 06, 2014 |
Drugs and Companies using DEXRAZOXANE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 September, 2007
Treatment: Treatment of extravasation resulting from iv anthracycline chemotherapy
Dosage: INJECTABLE;INJECTION
More Information on Dosage
TOTECT family patents
